AstraZeneca strikes licensing deal with RQ Bio for SARS-CoV-2 targeting mAbs

AstraZeneca has signed a licensing deal with RQ Biotechnology (RQ Bio) to gain access to a portfolio of early-stage monoclonal antibodies (mAbs) targeted against Covid-19 ... Read More